tissue factor pathway inhibitor tfpi  (Danaher Inc)

Journal: Journal of Extracellular Vesicles

Article Title: Extracellular vesicles originating from melanoma cells promote dysregulation in haematopoiesis as a component of cancer immunoediting

doi: 10.1002/jev2.12471

Figure Lengend Snippet: Effect of angiogenesis inhibitors on bone marrow cells from female C57BL/6N mice. (a) Schematic illustration of ex‐vivo experimental design. (b) Effect of pazopanib (VEGF inhibitor) on the inhibition of tEVs‐induced bone marrow cell proliferation. (c) Effect of pioglitazone (osteopontin inhibitor) on the inhibition of tEVs‐induced bone marrow cell proliferation. (d) Effect of epicatechin (ADAMTS‐1 inhibitor) on the inhibition of tEVs‐induced bone marrow cell proliferation. (e) Effect of rmTFPI (tissue factor pathway inhibitor) on the inhibition tEVs‐induced bone marrow cell proliferation. The cells were treated either inhibitors alone or with inhibitors in combination with 5e9 tEVs. The data are presented as means (±SD, n = 3). Statistical significance (* p < 0.01, *** p < 0.001, and **** p < 0.0001) between experimental groups was calculated with using one‐way analysis of variance (ANOVA) with each value Tukey's multiple comparisons test.

Article Snippet: The inhibitory effect of pazopanib, a VEGFR inhibitor (SML3076, Sigma‐Aldrich, Germany), pioglitazone, an osteopontin inhibitor (E6910, Sigma‐Aldrich, Germany), epigallocatechin, an ADAMTS‐1 inhibitor (E3768, Sigma‐Aldrich, Germany), and rmTFPI Protein, a recombinant mouse tissue factor pathway inhibitor (2975‐PI, R&D Systems) were evaluated to assess their abilities to prevent the possible impact of tEVs on the hematopoietic.

Techniques: Ex Vivo, Inhibition